Abu Dhabi, Sep 11, 2012 : Neopharma, the leading generic pharmaceutical manufacturing facility in Abu Dhabhi, launched Dr. B. R. Shetty Research Centre, its world class research and development centre in Musaffah on September 10, Monday.
Speaking on the occasion, Neopharma MD and CEO Dr. B. R. Shetty said that the future of healthcare can be assured by providing hi-tech pharmaceutical products and healthcare services to the UAE community and the neighboring regions. Dedicating the Dr. B. R. Shetty Research Centre to his community, Dr. B. R. Shetty said that it is the cornerstone of innovation in pharmaceutical foundations, new drug delivery systems, nanotechnology and biological products for chronic or life-threatening diseases.
Further, he spoke of the research centre as a pivotal hub for the development of novel drug delivery systems aimed at the treatment of diabetes mellitus and cancer. In this attempt, Neopharma has introduced modified release glyclazide (Glyka MR) and extended release metformin tablets (Neomet XR) for diabetes, Clarithromycin modified release (Resclar MR) tablets in the antibiotic segment and Diclofenac sustained release tablets (Neoflam retard).
He said that the research centre has collaborated with Arkansas University for the development of microfiber nanotechnology for glucose sensors and nanotechnology based microchips for neurodegenerative disorders. In collaboration with Biocon, the biotech leader, he said that the research centre has introduced novel nanotech product called albumim bound paclitaxel for breast cancer.
The chief guest of the occasion, Mr. M. D. Mallya, chairman and managing director of Bank of Baroda, said that Dr. Shetty has always been the epitome of service to mankind, adding that the research centre is another feature in the doctor’s cap. Stating that Neopharma has aptly named the research centre in his honor, he expressed confidence that human welfare will continue to be the priority of the research centre. He wished the research team well.
M. D. Mallya, chairman and MD of Bank of Baroda; V. H. Thatte, general manager (international) GCC, Bank of Baroda, Mumbai; K. V. Rama Moorthy, CEO (GCC operations), Bank of Baroda; Narendra K. Batra, deputy general manager, Abu Dhabi Branch, Bank of Baroda; Dr. Ahmed Zohbi, managing director of Amreet Trading; Sharad Bhandari, managing director of Ardent Advisory; Neopharma officers, media persons, and special guests were present at the inauguration ceremony.
Neopharma, which was launched in 2003, is the premier pharmaceutical manufacturing company of UAE. It emphasizes research toward development of processes and products that are patent non-infringing, a route that can propel the company toward attaining leading position in the Middle East.
Neopharma follows global benchmarks in manufacturing technology and efficient control methods. Neopharma employs the latest automated PLC controlled machines, procured from the world’s best manufacturers for the entire manufacturing and development process in compliance with international regulations for pharmaceutical development, the ICH Q8 guidelines.
Neopharma has also partnered with leading multinational companies for the development and manufacture of new formulations.